Type

Journal Article

Authors

Emer P Reeves
Noel G McElvaney
Thomas McEnery
Laura T Fee
Danielle M Dunlea

Subjects

Medicine & Nursing

Topics
neutrophil therapy liver disease individuals risk factor anti inflammatory respiratory disease alpha 1 antitrypsin

The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals. (2018)

Abstract Alpha-1 antitrypsin (AAT) is the most abundant serine protease inhibitor circulating in the blood. AAT deficiency (AATD) is an autosomal codominant condition affecting an estimated 3.4 million individuals worldwide. The clinical disease associated with AATD can present in a number of ways including COPD, liver disease, panniculitis and antineutrophil cytoplasmic antibody vasculitis. AATD is the only proven genetic risk factor for the development of COPD, and deficient individuals who smoke are disposed to more aggressive disease. Principally, AAT is a serine protease inhibitor; however, over the past number of years, the assessment of AAT as simply an antiprotease has evolved, and it is now recognized that AAT has significant anti-inflammatory properties affecting a wide range of cells, including the circulating neutrophil.
Collections Ireland -> Royal College of Surgeons in Ireland -> PubMed

Full list of authors on original publication

Emer P Reeves, Noel G McElvaney, Thomas McEnery, Laura T Fee, Danielle M Dunlea

Experts in our system

1
Emer P Reeves
Royal College of Surgeons in Ireland
Total Publications: 63
 
2
Noel G McElvaney
Royal College of Surgeons in Ireland
Total Publications: 194
 
3
Laura T Fee
Royal College of Surgeons in Ireland
Total Publications: 3
 
4
Danielle M Dunlea
Royal College of Surgeons in Ireland
Total Publications: 6